Apellis Pharma receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Apellis Pharmaceuticals Inc (APLS)
Apellis Pharmaceuticals Inc stock price live, this page displays NASDAQ APLS stock exchange data. View the APLS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Apellis Pharmaceuticals Inc real time stock price chart below.
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 18.75.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is ""APLS.""
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
What Is the Apellis Pharmaceuticals Inc Stock Price Today?
The Apellis Pharmaceuticals Inc stock price today is 18.75.
What Is the Stock Symbol for Apellis Pharmaceuticals Inc?
The stock symbol for Apellis Pharmaceuticals Inc is ""APLS.""
What Stock Exchange Does Apellis Pharmaceuticals Inc Trade On?
Apellis Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Apellis Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Apellis Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the APLS quote. (ISIN: US03753U1060)
18.75
-0.84(-4.29%)
Closed·
After Hours
19.11+0.36(+1.92%)
·
Fair Value
An estimate of a Apellis Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.72
20.01
52 wk Range
16.10
41.94
APLS Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Earnings results expected in 3 days
More Info
Fair Value
An estimate of a Apellis Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.7220.01
52 wk Range
16.1041.94
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
APLS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Apellis Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
35.60
Upside
+89.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Liquid assets exceed short term obligations
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Apellis Pharmaceuticals Inc Company Profile
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Apellis Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Apellis Pharmaceuticals missed Q1 2025 estimates with EPS of -$0.74 and revenue of $166.8M, leading to a 2.56% stock price drop
- Cyfovri maintains 60% market share in geographic atrophy, but net product revenue declined; Empaveli awaits potential new indications approval
- Cash and equivalents stand at $358M; company expects stable operating expenses compared to 2024
- Empaveli launch for C3G and iCMPGN anticipated in Q3 2025; pivotal studies in other areas initiated
- Inventory dynamics, competition, and potential tariff impacts pose risks to future performance
Last Updated: 07/05/2025, 15:20
Read Full TranscriptCompare APLS to Peers and Sector
Metrics to compare | APLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.0x | −4.5x | −0.5x | |
PEG Ratio | −0.23 | −0.15 | 0.00 | |
Price/Book | 15.0x | 3.7x | 2.6x | |
Price / LTM Sales | 3.2x | 12.8x | 3.2x | |
Upside (Analyst Target) | 65.8% | 117.9% | 41.6% | |
Fair Value Upside | Unlock | 15.1% | 6.0% | Unlock |
Analyst Ratings
13 Buy
9 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 35.60
(+89.87% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
-0.74 / -0.34
Revenue / Forecast
166.80M / 197.77M
People Also Watch
FAQ
What Stock Exchange Does Apellis Pharma Trade On?
Apellis Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Apellis Pharma?
The stock symbol for Apellis Pharma is "APLS."
What Is the Apellis Pharma Market Cap?
As of today, Apellis Pharma market cap is 2.37B.
What Is Apellis Pharma's Earnings Per Share (TTM)?
The Apellis Pharma EPS (TTM) is -1.80.
When Is the Next Apellis Pharma Earnings Date?
Apellis Pharma will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is APLS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Apellis Pharma Stock Split?
Apellis Pharma has split 0 times.
How Many Employees Does Apellis Pharma Have?
Apellis Pharma has 708 employees.
What is the current trading status of Apellis Pharma (APLS)?
As of 28 Jul 2025, Apellis Pharma (APLS) is trading at a price of 18.75, with a previous close of 19.59. The stock has fluctuated within a day range of 18.72 to 20.01, while its 52-week range spans from 16.10 to 41.94.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.